|  |   | 
		| (2 intermediate revisions not shown.) | 
| Line 1: | Line 1: | 
|  |  |  |  | 
|  | ==Solution structure of de novo macrocycle design7.3a== |  | ==Solution structure of de novo macrocycle design7.3a== | 
| - | <StructureSection load='6bf3' size='340' side='right'caption='[[6bf3]], [[NMR_Ensembles_of_Models | 20 NMR models]]' scene=''> | + | <StructureSection load='6bf3' size='340' side='right'caption='[[6bf3]]' scene=''> | 
|  | == Structural highlights == |  | == Structural highlights == | 
| - | <table><tr><td colspan='2'>[[6bf3]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BF3 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6BF3 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6bf3]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BF3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6BF3 FirstGlance]. <br> | 
| - | </td></tr><tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=DAS:D-ASPARTIC+ACID'>DAS</scene>, <scene name='pdbligand=DPR:D-PROLINE'>DPR</scene>, <scene name='pdbligand=DTH:D-THREONINE'>DTH</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR, 20 models</td></tr> | 
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6bf3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6bf3 OCA], [http://pdbe.org/6bf3 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6bf3 RCSB], [http://www.ebi.ac.uk/pdbsum/6bf3 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6bf3 ProSAT]</span></td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DAS:D-ASPARTIC+ACID'>DAS</scene>, <scene name='pdbligand=DPR:D-PROLINE'>DPR</scene>, <scene name='pdbligand=DTH:D-THREONINE'>DTH</scene></td></tr> | 
|  | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6bf3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6bf3 OCA], [https://pdbe.org/6bf3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6bf3 RCSB], [https://www.ebi.ac.uk/pdbsum/6bf3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6bf3 ProSAT]</span></td></tr> | 
|  | </table> |  | </table> | 
|  | <div style="background-color:#fffaf0;"> |  | <div style="background-color:#fffaf0;"> | 
| Line 20: | Line 21: | 
|  | __TOC__ |  | __TOC__ | 
|  | </StructureSection> |  | </StructureSection> | 
|  | + | [[Category: Homo sapiens]] | 
|  | [[Category: Large Structures]] |  | [[Category: Large Structures]] | 
| - | [[Category: Baker, D]] | + | [[Category: Baker D]] | 
| - | [[Category: Hosseinzadeh, P]] | + | [[Category: Hosseinzadeh P]] | 
| - | [[Category: Pardo-Avila, F]] | + | [[Category: Pardo-Avila F]] | 
| - | [[Category: Shortridge, M D]] | + | [[Category: Shortridge MD]] | 
| - | [[Category: Varani, G]] | + | [[Category: Varani G]] | 
| - | [[Category: De novo]]
 | + |  | 
| - | [[Category: De novo protein]]
 | + |  | 
| - | [[Category: Macrocycle]]
 | + |  | 
|  |   Structural highlights 
  Publication Abstract from PubMed Mixed-chirality peptide macrocycles such as cyclosporine are among the most potent therapeutics identified to date, but there is currently no way to systematically search the structural space spanned by such compounds. Natural proteins do not provide a useful guide: Peptide macrocycles lack regular secondary structures and hydrophobic cores, and can contain local structures not accessible with l-amino acids. Here, we enumerate the stable structures that can be adopted by macrocyclic peptides composed of l- and d-amino acids by near-exhaustive backbone sampling followed by sequence design and energy landscape calculations. We identify more than 200 designs predicted to fold into single stable structures, many times more than the number of currently available unbound peptide macrocycle structures. Nuclear magnetic resonance structures of 9 of 12 designed 7- to 10-residue macrocycles, and three 11- to 14-residue bicyclic designs, are close to the computational models. Our results provide a nearly complete coverage of the rich space of structures possible for short peptide macrocycles and vastly increase the available starting scaffolds for both rational drug design and library selection methods.
 Comprehensive computational design of ordered peptide macrocycles.,Hosseinzadeh P, Bhardwaj G, Mulligan VK, Shortridge MD, Craven TW, Pardo-Avila F, Rettie SA, Kim DE, Silva DA, Ibrahim YM, Webb IK, Cort JR, Adkins JN, Varani G, Baker D Science. 2017 Dec 15;358(6369):1461-1466. doi: 10.1126/science.aap7577. PMID:29242347[1]
 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
   References ↑ Hosseinzadeh P, Bhardwaj G, Mulligan VK, Shortridge MD, Craven TW, Pardo-Avila F, Rettie SA, Kim DE, Silva DA, Ibrahim YM, Webb IK, Cort JR, Adkins JN, Varani G, Baker D. Comprehensive computational design of ordered peptide macrocycles. Science. 2017 Dec 15;358(6369):1461-1466. doi: 10.1126/science.aap7577. PMID:29242347 doi:http://dx.doi.org/10.1126/science.aap7577
 
 |